Epitalon — also spelled epithalon, and sometimes sold by its sequence Ala-Glu-Asp-Gly — is a four-amino-acid peptide sold as an anti-ageing compound on the claim that it switches on telomerase. It has never been approved anywhere. In 2026 it was nominated for US compounding as an injection for insomnia, which obliged FDA's reviewers to collect every safety record they could find. Their briefing document is the most complete account of epitalon's side effects that exists, and its central finding is an absence. This page reports what it found, adds the arithmetic it implies, and sets out the one concern FDA raised that the market does not mention. Why the human studies usually cited for epitalon were done with a different substance is on our epitalon dosage page.
Where the record comes from
The source is FDA's briefing document on epitalon-related bulk drug substances (free base and acetate) for the Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026 (FDA briefing document). Its reviewers searched PubMed, Embase, the Cochrane database, FAERS, FDA's food and supplement complaint system and ClinicalTrials.gov, plus the nominators' submissions. The nomination was for insomnia, as a subcutaneous injection at 10 mg/mL or 3,000 mcg/mL.
What they found, in one table:
| What FDA looked for | What it found |
|---|---|
| Clinical studies assessing safety, any route | None |
| Pharmacokinetic data in people | None |
| FAERS adverse-event reports, through 2025-12-08 | Zero |
| Food, supplement and cosmetic complaints, through 2025-12-05 | Zero |
| Human studies of any kind with epitalon itself | Three — two sublingual, one parabulbar injection |
| Acute, repeat-dose, developmental and reproductive toxicity | None |
| Two-year carcinogenicity study | None |
| Genotoxicity | Three small mouse studies, one fixed dose each |
Our own checks on 2026-10-11 agree: ClinicalTrials.gov returned zero studies for epitalon, epithalon or AEDG, and an openFDA adverse-event query for epitalon returned no matches.
The three human studies, and what they said about safety
FDA found epitalon itself given to people in three studies. Two gave it sublingually to night-shift workers to look at circadian genes and a melatonin metabolite (Khavinson and colleagues, 2021; Ivko and colleagues, 2021). The third gave it as a parabulbar injection — beside the eyeball — in patients with retinitis pigmentosa (Khavinson and colleagues, 2002). None was designed to measure safety.
The one with details FDA could read gave 20 people aged 40 to 50 three sprays twice a day for 20 days, at 0.5 mg of peptide a day. FDA notes that it did not report safety data. The only other line on tolerability is a 2007 conference abstract by Korkushko and colleagues stating that pineal preparations — epitalon and epithalamin together — had "no side effects" in elderly people. FDA could not evaluate the full paper, which is in Russian, and the abstract gives no route, dose, duration, number of subjects or method of collecting adverse events.
That is the whole human safety record. An empty record is not a finding of safety — our peptide side-effects overview explains why the absence of reports usually means the absence of anyone counting.
The arithmetic between the study and the market
FDA also recorded what clinic websites say: epitalon "is typically administered" by subcutaneous injection or orally, at 5 mg to 10 mg a day, often in cycles.
Set beside the one human course with a stated dose, the gap is large. Our arithmetic:
| Daily amount | Total | |
|---|---|---|
| Ivko 2021 sublingual study, 20 days | 0.5 mg | 10 mg over the course |
| Clinic-stated range, per FDA's briefing | 5–10 mg | 10 mg reached in 1–2 days |
| Ratio, clinic daily figure ÷ study daily amount | — | 10× to 20× |
The study's figure was sublingual and the clinic figures are mostly injected, so the two are not the same exposure — no one has measured how much of either reaches the blood. What the table shows is that the amounts sold sit an order of magnitude above the only course anyone has reported giving people, and that no safety observation exists at either.
What FDA found in the animal work
- Genotoxicity. Two papers from one research group counted chromosome damage in the bone marrow of four female mice per group given 1 µg a day for five days a month, and reported fewer aberrations with epitalon — about 20% fewer in one strain and 30% in another. A third study gave mice a single 5 µg/kg dose and found no rise in micronuclei. FDA's reading: each used one fixed dose, the control data in the chromosome work were borrowed from four saline-treated mice used in another peptide's study, and none can establish whether epitalon is genotoxic.
- Tumours and lifespan. Three studies from that research group reported fewer spontaneous tumours and longer lifespans in female mice given epitalon intermittently. FDA notes the exposure was short — in the 2003 study, five days a month from two months of age, a maximum of about 22 weeks across a two-year life — and that a standard carcinogenicity study treats both sexes daily for two years.
- Everything else. No acute toxicity study, no repeat-dose toxicity study, no developmental or reproductive study. One study of fluorescently labelled epitalon in pregnant animals reported signal in fetal organs an hour after dosing; FDA said the data could not show the signal was the peptide.
The concern FDA raised that the market does not
Epitalon is sold on the claim that it activates telomerase and lengthens telomeres, the protective caps on chromosomes that shorten with age. FDA took that claim at face value and asked what it would mean if true. Its answer: long telomeres are generally associated with an increased risk of malignant tumours, so continuous exposure to a substance that extends them "could enable cells to evade senescence and become cancerous". In its conclusion FDA wrote that "from the mechanistic standpoint, epitalon has the potential to be carcinogenic", and that the mouse studies were too limited to answer the question either way.
This is not a finding that epitalon causes cancer; nothing has tested that. It is a statement that the property the compound is marketed on is the same property a toxicologist would want a two-year study for, and no such study exists.
Immunogenicity, aggregation and the vial
FDA's general peptide cautions apply. A peptide injected under the skin can provoke antibodies — subcutaneous injection is more immunogenic than intravenous — and peptides as short as two amino acids have been shown to aggregate, which raises that risk. FDA found no study of either for epitalon. It also found epitalon not well characterised as a substance: several salts and derivatives are sold under the same common name, and the certificate of analysis supplied with the nomination listed no bioburden or endotoxin test. What sterility and endotoxin testing do and do not show is covered in how to read a COA; research-labelled vials carry none of the controls FDA found missing even here — see what research-use-only labelling means.
The 2026 advisory vote
FDA recommended against adding epitalon to the 503A bulks list. At the meeting on July 24, 2026 the committee voted 7 to 5 in favour, with one abstention, according to trade-press reports — with MOTS-c, one of the two narrowest margins among the six peptides it backed. The vote is advice to FDA, not an approval, and it does not create the safety data the briefing found missing. How the list works and where the other nominated peptides stand is on our 503A category 2 page; the one peptide the committee rejected is covered on our DSIP side-effects page.
What the record does not contain
- Any adverse-event data from a human study — the one study with a stated dose did not report any.
- Any pharmacokinetic measurement — how much reaches the blood, by any route, and for how long.
- Any exposure longer than 20 days with a stated dose.
- Any toxicity study of the kind a new drug needs before a first human trial.
- Any study in men among the animal genotoxicity and tumour work.
Anyone connecting a symptom to epitalon, or weighing its use alongside sleep medicines, cancer history or a family history of cancer, should take the question to a clinician. Peptide Lexicon's epitalon entry covers what the peptide is.
Sources and dates
- FDA. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23–24, 2026: Epitalon-related bulk drug substances (epitalon free base and epitalon acetate). https://www.fda.gov/media/193345/download — sections I (nomination), II.B.2 (historical use), II.D.1 (nonclinical, incl. genotoxicity and carcinogenicity), II.D.2 (human safety) and III (conclusion). Read 2026-10-11.
- Ivko OM et al. 2021, sublingual Ala-Glu-Asp-Gly in 20 subjects; Khavinson VKh et al. 2021 and 2002; Korkushko OV et al. 2007 abstract; Anisimov VN et al. 2001, 2002, 2003; Rosenfeld SV et al. 2002 — as summarised in FDA's briefing.
- ClinicalTrials.gov API v2, terms "epitalon", "epithalon" and "AEDG": 0 studies each, queried 2026-10-11.
- openFDA drug adverse event endpoint, medicinal product "epitalon": no matches, queried 2026-10-11.
- Committee vote: trade-press reports of the July 24, 2026 meeting, as recorded on our epitalon dosage page (read 2026-09-13).